GSK plc
—- Market cap
- —
- Debt
- +$44.87B
- Cash
- −$3.40B
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GSK stock price vs BDN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BDN's multiple
Needs BDN P/E.
Implied fair value · at GSK's multiple
Needs EPS (TTM) is negative, GSK P/E.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · BDN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
GSK plc · implied price per share
Bear
$4.93
Base
$5.80
Bull
$6.67
BRANDYWINE REALTY TRUST · implied price per share
Bear
$0.11
Base
$0.13
Bull
$0.15
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
3.23x
Net debt / EBITDA
Leverage against operating earnings
5.76x
8.84x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$34.65M
Total debt
Interest-bearing obligations outstanding
$44.87B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
BXP, Inc.
GSK vs BXP
HIGHWOODS PROPERTIES, INC.
GSK vs HIW
KILROY REALTY CORP
GSK vs KRC
SL GREEN REALTY CORP
GSK vs SLG
VORNADO REALTY TRUST
GSK vs VNO
$2.56B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.